WCM
GILD icon

Wealthcare Capital Management’s Gilead Sciences GILD Stock Holding History

Wealthcare Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-137
Closed -$9K – 309
2021
Q1 		$9K Buy
+137
New +$8.83K ﹤0.01% 290
2020
Q2 		– Sell
-34
Closed -$3K – 121
2020
Q1 		$3K Sell
34
-68
-67% -$4.7K ﹤0.01% 207
2019
Q4 		$7K Buy
+102
New +$6.64K ﹤0.01% 215
2015
Q2 		– Sell
-270
Closed -$26K – 575
2015
Q1 		$26K Buy
+270
New +$27.4K ﹤0.01% 359
2014
Q4 		– Sell
-93
Closed -$10K – 222
2014
Q3 		$10K Buy
+93
New +$9.11K ﹤0.01% 149

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Wealthcare Capital Management's GILD Position: Q2 2021 in Review

Wealthcare Capital Management sold out of Gilead Sciences (GILD) in Q2 2021, closing a stake of 137 shares — an estimated $9K sold.

Wealthcare Capital Management first reported a position in GILD in Q3 2014 and held it in 5 quarters. The position peaked at $26K in Q1 2015. 1,544 funds tracked by Wall St. Rank hold GILD as of Q2 2021.

  • Wealthcare Capital Management reported no remaining Gilead Sciences position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Capital Management sold 137 Gilead Sciences shares in Q2 2021, an estimated $9K.
  • Wealthcare Capital Management first reported a position in Gilead Sciences in Q3 2014 and held it in 5 quarters.
  • Wealthcare Capital Management's Gilead Sciences position peaked at $26K in Q1 2015.
  • 1,544 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2021.

Based on Wealthcare Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.